End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

1-2 years >20 visits Efficacy phase (II)Confirmation phase (III)Cost Reimbursement Investigational Medicines InjectionCardiologyInternal MedicineNephrology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Sodium Chloride Solution 0.9%

Sodium chloride 0.9% is a sterile salt solution used to replace fluids and electrolytes, hydrate patients, and clean wounds or body cavities.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Clazakizumab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Abteilung für Innere Medizin und Gastroenterologie, Hepatologie, Endokrinologie, Rheumatologie

Klagenfurt am Wörthersee, Austria

Klinik Hietzing

3rd Department of Medicine

Perchtoldsdorf, Austria

Medical University Of Vienna

Innere Medizin III, Nephrologie und Dialyse

Vienna, Austria

Sponsor: CSL Behring LLC

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.